We next tested the sensitivity of SPRY2‐deficient cells to the CYP17A1 inhibitor abiraterone, which improves the treatment response of prostate cancer patients when combined with standard‐of‐care ADT (James et al, 2017). The gene discussed is CYP17A1; the disease is prostate cancer.